Skip to main content

bioAffinity Technologies, Inc 10-Q for FY2026 Q3

bioAffinity Technologies, Inc. (BIAF)

10-Q 2026-11-06 For: 2026-09-30
View Original
Added on November 06, 2026

About this 10-Q

bioAffinity Technologies, Inc filed this 10-Q on November 6, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

bioAffinity Technologies reported a net loss of $12.3 million for the nine months ended September 30, 2026, and management concluded there is substantial doubt about its ability to continue as a going concern. Cash and cash equivalents were $2.6 million at September 30, 2026, and $4.6 million as of November 3, 2026, which the company expects will support operations through March 2027. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$1.07M
down 26.0% from $1.45M a year earlier
Net loss
$5.28M
compared with a net loss of $5.05M a year earlier
Diluted EPS
-$5.89
compared with -$71.05 a year earlier